Stocks Health care TELO
NASDAQ · Health careTelomir Pharmaceuticals, Inc. (TELO)
It posted a net loss of $5.9M. At June 30, 2026 it held $5.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Telomir Pharmaceuticals, Inc.
- Net worth
- Telomir Pharmaceuticals, Inc. has a market value (market cap) of $47.5M at the latest share price, and shareholders' equity of $5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $3.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Telomir Pharmaceuticals, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Telomir Pharmaceuticals, Inc. does
Telomir Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TELO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$10.4M | -$0.33 | n/a |
| 2024 | n/a | -$16.5M | -$0.56 | n/a |
| 2023 | n/a | -$13.1M | $0.48 | n/a |
| 2023 | n/a | -$854.1K | -$0.03 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Telomir Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026Material agreement8-KTelomir Pharmaceuticals raised approximately $5.6 million through a common stock private placement to fund clinical development.
- September 17, 2026
- September 16, 2026
- September 14, 2026
- August 19, 2026Additional proxy material DEFA14A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 10, 2026
- July 28, 2026Proxy statement DEF 14A
- June 15, 2026
Insider trades
What the people running Telomir Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 22, 2026 | Aminov ErezCEO and Chairman, Director | Other change | 7,319,710 | $10M |
Who owns TELO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity13G, passive | 5.17% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 33 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Vanguard Capital Management LLC | 1,613,639 | +618,266 |
| Geode Capital Management, LLC | 338,875 | +89,789 |
| BlackRock, Inc. | 280,472 | -8,726 |
| Vanguard Fiduciary Trust Co | 225,304 | +89,763 |
| Northern Trust Corp | 61,532 | +19,688 |
| State Street Corp | 58,600 | 0 |
| Bank of New York Mellon Corp | 51,454 | 0 |
| Captrust Financial Advisors | 51,194 | new |
| Osaic Holdings, Inc. | 41,490 | +5,695 |
| World Investment Advisors | 37,037 | 0 |
| OneDigital Investment Advisors LLC | 23,000 | 0 |
| Qube Research & Technologies Ltd | 21,792 | new |
| Praetorian Wealth Management, Inc. | 20,000 | 0 |
| Vestmark Advisory Solutions, Inc. | 13,600 | +500 |
| Citadel Advisors LLC | 13,266 | new |
| Morton Capital Management LLC | 12,658 | 0 |
| Two Sigma Securities, LLC | 12,616 | new |
| Clearstead Advisors, LLC | 12,530 | 0 |
| NorthCrest Asset Manangement, LLC | 12,119 | new |
| Kestra Private Wealth Services, LLC | 11,000 | 0 |
Insiders
1 insiders reported holding 7,319,710 shares in total, about $5.1M at the last price.
| Holder | Shares |
|---|---|
| Aminov ErezCEO and Chairman, Director | 7,319,710 |
Questions about TELO
What does Telomir Pharmaceuticals, Inc. do?
Telomir Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as TELO. Its shares trade on NASDAQ under the ticker TELO.
What is Telomir Pharmaceuticals, Inc.'s net worth?
Telomir Pharmaceuticals, Inc. has a market value (market cap) of $47.5M at the latest share price, and shareholders' equity of $5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Telomir Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $5.9M.
When did Telomir Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from October 6, 2026.
When is Telomir Pharmaceuticals, Inc.'s next earnings report?
Telomir Pharmaceuticals, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TELO with
Follow TELO
Get an email when Telomir Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Telomir Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.